Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.

We compared the initial and long-term effects of the beta-adrenergic agonist pirbuterol in 12 patients with chronic congestive heart failure. The drug's initial effect was a 35 per cent increase in cardiac index, but there was no significant change in heart rate or mean arterial pressure. After one month of therapy, the mean cardiac index and ejection fraction had returned to base-line values, and no clinical effect was evident in most patients. This apparent tolerance was not accompanied by changes in heart rate, blood pressure, or body weight, and it occurred in the presence of therapeutic drug levels during long-term therapy. The density of beta-adrenergic receptors on lymphocytes from patients treated with pirbuterol was significantly depressed as compared with that of patients with heart failure of comparable severity but not treated with pirbuterol. We conclude that tolerance to the hemodynamic and clinical effects of pirbuterol develops during long-term administration; this tolerance may be related to a decrease in myocardial or vascular beta-adrenergic receptors or both.

[1]  M. Weinberger,et al.  Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. , 1981, The American journal of medicine.

[2]  E. Amsterdam,et al.  Hemodynamic Effects of Oral Pirbuterol in Chronic Severe Congestive Heart Failure , 1981, Circulation.

[3]  E. Braunwald,et al.  Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. , 1980, Annals of internal medicine.

[4]  C. Leier,et al.  Tolerance to dobutamine after a 72 hour continuous infusion. , 1980, The American journal of medicine.

[5]  E. Braunwald,et al.  Long-term therapy of heart failure with prazosin: a randomized double blind trial. , 1980, The American journal of cardiology.

[6]  R. Lefkowitz.  Direct binding studies of adrenergic receptors: biochemical, physiologic, and clinical implications. , 1979, Annals of internal medicine.

[7]  M. Pfisterer,et al.  Left Ventricular Volumes by Gated Equilibrium Radionuclide Angiography: A New Method , 1979, Circulation.

[8]  E. Braunwald,et al.  Hemodynamic assessment of amrinone. A new inotropic agent. , 1978, The New England journal of medicine.

[9]  P. Insel,et al.  Decreased beta-adrenergic receptors on polymorphonuclear leukocytes after adrenergic therapy. , 1978, The New England journal of medicine.

[10]  J. A. Thomas,et al.  Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.

[11]  J. Peuler,et al.  Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. , 1977, Life sciences.

[12]  S. Holgate,et al.  β-ADRENERGIC AGONIST RESISTANCE IN NORMAL HUMAN AIRWAYS , 1977, The Lancet.

[13]  I. Paterson,et al.  Effects of prolonged administration of pirbuterol by mouth in chronic asthma. , 1977, British journal of clinical pharmacology.

[14]  T. Chick,et al.  Subsensitivity of beta responses during therapy with a long-acting beta-2 preparation. , 1977, The Journal of allergy and clinical immunology.

[15]  F. Falkner,et al.  Selected ion monitoring assay for the bronchodilator pirbuterol. , 1976, Biomedical mass spectrometry.

[16]  M. Caron,et al.  Regulation of adenylate cyclase coupled beta-adrenergic receptors. , 1976, Recent progress in hormone research.

[17]  R. Lefkowitz,et al.  Identification of beta-adrenergic receptors in human lymphocytes by (-) (3H) alprenolol binding. , 1976, The Journal of clinical investigation.

[18]  G. Williams,et al.  Double antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasma. , 1973, The Journal of laboratory and clinical medicine.

[19]  C. Mogensen.  The glomerular permeability determined by dextran clearance using Sephadex gel filtration. , 1968, Scandinavian journal of clinical and laboratory investigation.